



*Edited by Niels Behrendt*

## **Matrix Proteases in Health and Disease**



**WILEY-  
VCH**

**WILEY-VCH Verlag GmbH & Co. KGaA**

## The Editor

### **Dr. Niels Behrendt**

The Finsen Laboratory  
Dept. 37.35, Rigshospitalet/Biotech Research  
and Innovation Centre (BRIC), the University  
of Copenhagen  
Ole Maaloes Vej 5  
2200 Copenhagen N  
Denmark

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

### **British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

### **Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2012 Wiley-VCH Verlag & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Cover Design** Grafik-Design Schulz, Fußgönheim

**Typesetting** Laserwords Private Limited, Chennai, India

**Printing and Binding** Markono Print Media Pte Ltd, Singapore

**Print ISBN:** 978-3-527-32991-5  
**ePDF ISBN:** 978-3-527-64935-8  
**ePub ISBN:** 978-3-527-64934-1  
**mobi ISBN:** 978-3-527-64933-4  
**oBook ISBN:** 978-3-527-64932-7

## Contents

**Preface** XIII

**List of Contributors** XV

**Introduction** 1

*Niels Behrendt*

- 1 Matrix Proteases and the Degradome** 5  
*Clara Soria-Valles, Carlos López-Otín, and Ana Gutiérrez-Fernández*
- 1.1 Introduction 5
- 1.2 Bioinformatic Tools for the Analysis of Complex Degradomes 6
- 1.3 Evolution of Mammalian Degradomes 8
  - 1.3.1 Human Degradome 8
  - 1.3.2 Rodent Degradomes 10
  - 1.3.3 Chimpanzee Degradome 10
  - 1.3.4 Duck-Billed Platypus Degradome 11
  - 1.3.5 Other Degradomes 12
- 1.4 Human Diseases of Proteolysis 13
- 1.5 Matrix Proteases and Their Inhibitors 14
- Acknowledgments 17
- References 17
  
- 2 The Plasminogen Activation System in Normal Tissue Remodeling** 25  
*Vincent Ellis*
- 2.1 Introduction 25
- 2.2 Biochemical and Enzymological Fundamentals 26
  - 2.2.1 Plasminogen 27
  - 2.2.2 Regulation of the Plasminogen Activation System 28
- 2.3 Biological Roles of the Plasminogen Activation System 30
  - 2.3.1 Congenital Plasminogen Deficiencies 31
  - 2.3.2 Intravascular Fibrinolysis 32
  - 2.3.3 Extravascular Fibrinolysis – Ligneous Conjunctivitis 32

2.3.4	Congenital Inhibitor Deficiencies	33
2.4	Tissue Remodeling Processes	34
2.4.1	Wound Healing	34
2.4.2	Vascular Remodeling	35
2.4.3	Fibrosis	36
2.4.4	Nerve Injury	38
2.4.5	Rheumatoid Arthritis	38
2.4.6	Complex Tissue Remodeling	40
2.4.7	Angiogenesis	40
2.4.8	uPAR – Cinderella Finds Her Shoe	42
2.5	Conclusions	44
	References	45
<b>3</b>	<b>Physiological Functions of Membrane-Type Metalloproteases</b>	<b>57</b>
	<i>Kenn Holmbeck</i>	
3.1	Introduction	57
3.2	Historical Perspective	57
3.3	Activation of the Activator	59
3.4	Potential Roles of MT-MMPs and Discovery of a Human MMP Mutation	59
3.5	MT-MMP Function?	60
3.6	Physiological Roles of MT1-MMP in the Mouse	61
3.7	MT1-MMP Function in Lung Development	63
3.8	MT1-MMP Is Required for Root Formation and Molar Eruption	64
3.9	Identification of Cooperative Pathways for Collagen Metabolism	64
3.10	MT-MMP Activity in the Hematopoietic Environment	65
3.11	Physiological Role of MT2-MMP	66
3.12	MT-Type MMPs Work in Concert to Execute Matrix Remodeling	67
3.13	MT4-MMP – an MT-MMP with Elusive Function	69
3.14	MT5-MMP Modulates Neuronal Growth and Nociception	69
3.15	Summary and Concluding Remarks	70
	Acknowledgment	71
	References	71
<b>4</b>	<b>Bone Remodeling: Cathepsin K in Collagen Turnover</b>	<b>79</b>
	<i>Dieter Brömme</i>	
4.1	Introduction	79
4.2	Proteolytic Machinery of Bone Resorption and Cathepsin K	80
4.3	Specificity and Mechanism of Collagenase Activity of Cathepsin K	82
4.4	Role of Glycosaminoglycans in Bone Diseases	86
4.5	Development of Specific Cathepsin K Inhibitors and Clinical Trials	87
4.6	Off-Target and Off-Site Inhibition	89
4.7	Conclusion	91

	Acknowledgments	91
	References	91
<b>5</b>	<b>Type-II Transmembrane Serine Proteases: Physiological Functions and Pathological Aspects</b>	<b>99</b>
	<i>Gregory S. Miller, Gina L. Zoratti, and Karin List</i>	
5.1	Introduction	99
5.2	Functional/Structural Properties of TTSPs	99
5.3	Physiology and Pathobiology	104
5.3.1	Hepsin/TMPRSS Subfamily	104
5.3.2	Corin Subfamily	105
5.3.3	Matriptase Subfamily	106
5.3.4	HAT/DESC1 Subfamily	110
5.3.5	TTSPs in Cancer	111
	References	114
<b>6</b>	<b>Plasminogen Activators in Ischemic Stroke</b>	<b>127</b>
	<i>Gerald Schielke and Daniel A. Lawrence</i>	
6.1	Introduction	127
6.2	Rationale for Thrombolysis after Stroke	128
6.2.1	Clinical Trials: Overview	129
6.3	Preclinical Studies	131
6.3.1	Localization of PAs, Neuroserpin, and Plasminogen in the Brain	131
6.4	The Association of Endogenous tPA with Excitotoxic and Ischemic Brain Injury	134
6.4.1	Excitotoxicity	134
6.4.2	Focal Ischemia	135
6.4.3	Global Ischemia	137
6.5	Mechanistic Studies of tPA in Excitotoxic and Ischemic Brain Injury	137
6.5.1	tPA and the NMDA Receptor	137
6.5.2	tPA and the Blood–Brain Barrier	138
6.5.3	tPA and the Blood–Brain Barrier – MMPs	139
6.5.4	tPA and the Blood–Brain Barrier – LRP	140
6.6	tPA and the Blood–Brain Barrier–PDGF-CC	141
6.7	Summary	143
	Acknowledgments	144
	References	145
<b>7</b>	<b>Bacterial Abuse of Mammalian Extracellular Proteases during Tissue Invasion and Infection</b>	<b>157</b>
	<i>Claudia Weber, Heiko Herwald, and Sven Hammerschmidt</i>	
7.1	Introduction	157
7.2	Tissue and Cell Surface Remodeling Proteases	158
7.2.1	Matrix Metalloproteinases (MMPs)	158

7.2.2	A Disintegrin and Metalloproteinases (ADAMs)	160
7.2.3	A Disintegrin and Metalloproteinase with Thrombospondin Motif (ADAMTS)	161
7.3	Proteases of the Blood Coagulation and the Fibrinolytic System	162
7.3.1	Proteases of the Blood Coagulation System	162
7.3.2	Proteases of the Fibrinolytic System	164
7.4	Contact System	168
7.4.1	Mechanisms of Bacteria-Induced Contact Activation	169
7.5	Conclusion and Future Prospectives	170
	Acknowledgments	172
	References	172

## **8 Experimental Approaches for Understanding the Role of Matrix Metalloproteinases in Cancer Invasion** 181

*Elena Deryugina*

8.1	Introduction: Functional Roles of MMPs in Physiological Processes Involving the Induction and Sustaining of Cancer Invasion	181
8.2	EMT: a Prerequisite of MMP-Mediated Cancer Invasion or a Coordinated Response to Growth-Factor-Induced MMPs?	182
8.2.1	MMP-Induced EMT	183
8.2.2	EMT-Induced MMPs	185
8.3	Escape from the Primary Tumor: MMP-Mediated Invasion of Basement Membranes	186
8.3.1	<i>In vitro</i> Models of BM Invasion: Matrigel Invasion in Transwells	186
8.3.2	<i>Ex Vivo</i> Models of BM Invasion: Transmigration through the Intact BM	188
8.3.3	<i>In Vivo</i> Models of BM Invasion: Invasion of the CAM in Live Chick Embryos	189
8.4	Invasive Front Formation: Evidence for MMP Involvement <i>In Vivo</i>	189
8.4.1	MMP-Dependent Invasion in Spontaneous Tumors Developing in Transgenic Mice	190
8.4.2	MMP-Dependent Invasion of Tumor Grafts in MMP-Competent Mice	191
8.4.3	Invasion of MMP-Competent Tumor Grafts in MMP-Deficient Mice	192
8.5	Invasion at the Leading Edge: MMP-Mediated Proteolysis of Collagenous Stroma	193
8.5.1	Collagen Invasion in Transwells	193
8.5.2	Invasion of Collagen Matrices by Overlaid Tumor Cells	194
8.5.3	Models of 3D Collagen Invasion	195
8.5.4	Invasion of Collagenous Stroma <i>In Vivo</i>	196
8.5.5	Dynamic Imaging of ECM Proteolysis during Path-Making <i>In vitro</i> and <i>In Vivo</i>	197

8.6	Tumor Angiogenesis and Cancer Invasion: MMP-Mediated Interrelationships	197
8.6.1	Angiogenic Switch: MMP-9-Induced Neovascularization as a Prerequisite for Blood-Vessel-Dependent Cancer Invasion	198
8.6.2	Mutual Reliance of MMP-Mediated Angiogenesis and Cancer Invasion	200
8.6.3	Apparent Distinction between MMP-Mediated Tumor Angiogenesis and Cancer Invasion	201
8.7	Cancer Cell Intravasation: MMP-Dependent Vascular Invasion	202
8.8	Cancer Cell Extravasation: MMP-Dependent Invasion of the Endothelial Barrier and Subendothelial Stroma	204
8.8.1	Transmigration across Endothelial Monolayers <i>In Vitro</i>	204
8.8.2	Tumor Cell Extravasation <i>In Vivo</i>	205
8.9	Metastatic Site: Involvement of MMPs in the Preparation, Colonization, and Invasion of Distal Organ Stroma	206
8.9.1	MMPs as Determinants of Organ-Specific Metastases	207
8.9.2	MMP-Dependent Preparation of the PreMetastatic Microenvironment	208
8.9.3	Invasive Expansion of Cancer Cells at the Metastatic Site	210
8.10	Perspectives: MMPs in the Early Metastatic Dissemination and Awakening of Dormant Metastases	211
	References	212
<b>9</b>	<b>Plasminogen Activators and Their Inhibitors in Cancer</b>	<b>227</b>
	<i>Joerg Hendrik Leupold and Heike Allgayer</i>	
9.1	Introduction	227
9.2	The Plasminogen Activator System	228
9.2.1	Molecular Characteristics and Physiological Functions of the u-PA System	228
9.2.2	Expression in Cancer	230
9.2.3	Regulation of Expression of the u-PA System in Cancer	231
9.2.4	Regulation of Cell Signaling by the u-PA System	235
9.2.5	Conclusion	238
	References	238
<b>10</b>	<b>Protease Nexin-1 – a Serpin with a Possible Proinvasive Role in Cancer</b>	<b>251</b>
	<i>Tina M. Kousted, Jan K. Jensen, Shan Gao, and Peter A. Andreasen</i>	
10.1	Introduction – Serpins and Cancer	251
10.2	History of PN-1	252
10.3	General Biochemistry of PN-1	253
10.4	Inhibitory Properties of PN-1	254
10.5	Binding of PN-1 and PN-1-Protease Complexes to Endocytosis Receptors of the Low-Density Lipoprotein Receptor Family	257
10.6	Pericellular Functions of PN-1 in Cell Cultures	260



10.7	PN-1 Expression Patterns	261
10.7.1	Expression of PN-1 in Cultured Cells	261
10.7.2	Mechanisms of Transcriptional Regulation of PN-1 Expression	262
10.7.3	Expression of PN-1 in the Intact Organism	263
10.8	Functions of PN-1 in Normal Physiology	263
10.8.1	Reproductive Organs	263
10.8.2	Neurobiological Functions	264
10.8.3	Vascular Functions	265
10.9	Functions of PN-1 in Cancer	266
10.9.1	PN-1 Expression is Upregulated in Human Cancers, and a High Expression Is a Marker for a Poor Prognosis	266
10.9.2	Studies with Cell Cultures and Animal Tumor Models Indicate a Proinvasive Role of PN-1	267
10.10	Conclusions	270
	References	271

## 11 **Secreted Cysteine Cathepsins –Versatile Players in Extracellular Proteolysis** 283

*Fee Werner, Kathrin Sachse, and Thomas Reinheckel*

11.1	Introduction	283
11.2	Structure and Function of Cysteine Cathepsins	283
11.3	Synthesis, Processing, and Sorting of Cysteine Cathepsins	284
11.4	Extracellular Enzymatic Activity of Lysosomal Cathepsins	286
11.5	Endogenous Cathepsin Inhibitors as Regulators of Extracellular Cathepsins	286
11.6	Extracellular Substrates of Cysteine Cathepsins	287
11.7	Cysteine Cathepsins in Cancer: Clinical Associations	287
11.8	Cysteine Cathepsins in Cancer: Evidence from Animal Models	288
11.9	Molecular Dysregulation of Cathepsins in Cancer Progression	289
11.10	Extracellular Cathepsins in Cancer	289
11.11	Conclusions and Further Directions	290
	Acknowledgments	291
	References	291

## 12 **ADAMs in Cancer** 299

*Dorte Stautz, Sarah Louise Dombernowsky, and Marie Kveiborg*

12.1	ADAMs–Multifunctional Proteins	299
12.1.1	Structure and Biochemistry	299
12.1.2	Biological Functions	300
12.1.3	Pathological Functions	301
12.2	ADAMs in Tumors and Cancer Progression	301
12.2.1	Self-Sufficiency in Growth Signals	303
12.2.2	Evasion of Apoptosis	303
12.2.3	Sustained Angiogenesis	304
12.2.4	Tissue Invasion and Metastasis	305

12.2.5	Cancer-Related Inflammation	306
12.2.6	Tumor–Stroma Interactions	307
12.3	ADAMs in Cancer—Key Questions Yet to Be Answered	307
12.3.1	ADAM Upregulation	308
12.3.2	Isoforms	308
12.3.3	Proteolytic versus Nonproteolytic Effect	309
12.4	The Clinical Potential of ADAMs	309
12.4.1	Diagnostic or Prognostic Biomarkers	309
12.4.2	ADAMs as Therapeutic Targets	310
12.5	Concluding Remarks	311
	References	311
<b>13</b>	<b>Urokinase-Type Plasminogen Activator, Its Receptor and Inhibitor as Biomarkers in Cancer</b>	<b>325</b>
	<i>Tine Thurison, Ida K. Lund, Martin Illemann, Ib J. Christensen, and Gunilla Høyer-Hansen</i>	
13.1	Introduction	325
13.2	Breast Cancer	327
13.3	Colorectal Cancer	331
13.4	Lung Cancer	333
13.5	Gynecological Cancers	334
13.6	Prostate Cancer	335
13.7	Conclusion and Perspectives	337
	Acknowledgment	339
	Abbreviations	339
	References	339
<b>14</b>	<b>Clinical Relevance of MMP and TIMP Measurements in Cancer Tissue</b>	<b>345</b>
	<i>Omer Bashir, Jian Cao, and Stanley Zucker</i>	
14.1	Introduction	345
14.2	MMP Structure	346
14.3	MMP Biology and Pathology	346
14.4	Natural Inhibitors of MMPs	347
14.5	Regulation of MMP Function	347
14.5.1	MMPs in Cancer	347
14.6	Cancer Stromal Cell Production of MMPs	348
14.7	Anticancer Effects of MMPs	348
14.8	Tissue Levels of MMPs and TIMPs in Cancer Patients	349
14.8.1	Breast Cancer	349
14.8.2	Gastrointestinal (GI) Cancer	351
14.8.2.1	Colorectal Cancer	351
14.8.2.2	Gastric Cancer	353
14.8.2.3	Pancreatic Cancer	355
14.8.2.4	Non-Small-Cell Lung Cancer (NSCLC)	355

14.8.3	Genitourinary Cancers	357
14.8.3.1	Bladder Cancer	357
14.8.3.2	Renal Cancer	359
14.8.3.3	Prostate Cancer	359
14.8.3.4	Ovarian Cancer	359
14.8.4	Brain Cancer	363
14.9	Conclusions	364
	Acknowledgments	365
	References	365
<b>15</b>	<b>New Prospects for Matrix Metalloproteinase Targeting in Cancer Therapy</b>	<b>373</b>
	<i>Emilie Buache and Marie-Christine Rio</i>	
15.1	Introduction	373
15.2	Lessons Learned from Preclinical and Clinical Studies of MMPs in Cancer and Possible Alternatives	374
15.2.1	Improve Specificity/Affinity/Selectivity	374
15.2.2	Increase Knowledge of Multifaceted Activities for a given MMP	375
15.2.2.1	Target an Active MMP	375
15.2.2.2	Fully Characterize the Spatio-Temporal Function of Each MMP: the MMP-11 Example	376
15.2.3	Minimize Negative Side Effects	377
15.2.4	Optimize MMP Administration Schedule	378
15.3	Novel Generation of MMPs	379
15.3.1	Target the Hemopexin Domain	379
15.3.2	Antibodies as MMPs	379
15.3.3	Immunotherapy	380
15.4	Exploit MMP Function to Improve Drug Bioavailability	380
15.5	Conclusion	381
	Acknowledgments	381
	References	381
	<b>Index</b>	<b>389</b>